$3.600
-0.234 (-6.49%)收盘时
CPSH 资讯
CPSH 事件
CPS Technologies Receives First Defense Order
CPS Technologies announced that it has received its first product order from a defense-related customer for tungsten alloy components manufactured using the company's proprietary QuickSet Injection Molding process. The order, placed by a research group supporting the U.S. military, represents the largest contract of its kind received by the company to date. Additional details cannot be disclosed due to confidentiality provisions. The continued development of the company's QuickSet technology is supported through funding from an ongoing Small Business Technology Transfer award, previously disclosed, from the U.S. Army Combat Capabilities Development Command; the $1.15M Phase II contract, began in 2025 and is scheduled to continue through September 2027. Following the successful fulfillment of a smaller commercial order earlier in 2026, the Company now expects to complete its first defense-related contract later this year.
CPS Technologies Signs Long-Term Lease for 80,000 Square Feet
CPS Technologies announced the signing of a long-term lease for an 80,000-square-foot facility in Attleboro, Massachusetts. The new site is approximately twice the size of the company's current location.
Liquid Option Names See Borrow Rate Increases
Latest data shows the largest indicative borrow rate increases among liquid option names include: Almonty Industries Inc. Common Shares (ALM) 4.06% +3.37, Microvision (MVIS) 22.00% +2.11, Yellowstone Midco Holdings Ii, Llc (YSS) 59.46% +1.98, Beyond Meat (BYND) 40.88% +1.93, PureCycle Technologies (PCT) 8.36% +1.05, SAP (SAP) 2.28% +0.95, T-REX 2X INVERSE MSTR DAILY TARGET (MSTZ) 13.87% +0.52, Direxion S&P Biotech Bear 3X (LABD) 14.72% +0.47, CPS Technologies (CPSH) 4.20% +0.41, and One Stop Systems (OSS) 1.84% +0.39.
Liquid Option Borrow Rates Rise: PSEC 6.65%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Prospect Capital (PSEC) 6.65% +3.79, Angion Biomedica Corp (ELTX) 13.52% +1.76, GRANITESHARES 2X LONG MU DAILY ETF (MULL) 13.12% +1.61, Vivopower Plc (VIVO) 16.76% +0.70, Avalo Therapeutics (AVTX) 1.18% +0.65, KULR Technology Group (KULR) 6.76% +0.54, CPS Technologies (CPSH) 6.12% +0.52, Tradr 2X Long SNDK Daily ETF (SNXX) 8.43% +0.49, ASP Isotopes Inc (ASPI) 1.76% +0.38, and Boost Run Inc. (BRUN) 8.40% +0.38.
CPS Technologies Issues 1.2M Shares at $8.00 Each
CPS Technologies announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 1.2M shares of the company's common stock at a purchase price of $8.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 29, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the company from the offering are expected to be approximately $9.6M, before deducting the placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from this offering for general corporate purposes, which may include working capital, capital expenditures, commercialization of developing technologies and other investments.
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。